Abstract
Schizophrenia and Alzheimer's disease are characterised by abnormalities in glutamatergic pathways related to N-methyl-D-aspartate receptor hypofunction. Glycine is an N-methyl-D-aspartate receptor co-agonist; inhibition of glycine transporter 1 may improve N-methyl-D-aspartate receptor function. This phase I, randomised, two-part study evaluated the safety, tolerability and pharmacokinetic profile of BI 425809, a novel glycine transporter 1 inhibitor, in healthy male and female volunteers. Part 1 evaluated BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily in young subjects, and 25 mg or 50 mg once daily in elderly subjects. Each dose group comprised 12 subjects who received BI 425809 (n = 9) or placebo (n = 3) for 14 days (day 1: single dose; days 4-14: multiple dosing). Part 2 compared pharmacokinetic profiles in 12 subjects who received a single dose of BI 425809 25 mg in the morning and evening. Pharmacokinetic profiles were similarly shaped for all dose groups. Median time to maximum plasma concentration was 3.0-4.5 h with steady state being reached between days 6 and 10. Pharmacokinetic parameters demonstrated dose linearity at the predicted therapeutic exposure range of BI 425809 ≤ 25 mg once daily, but incre...Continue Reading
References
Dec 1, 1994·Biologicals : Journal of the International Association of Biological Standardization·M Haase
May 1, 1994·British Journal of Clinical Pharmacology·N Baber
May 3, 1997·Schizophrenia Research·D I VelliganA L Miller
Feb 3, 1998·Anesthesiology·T A BowdleP P Roy-Byrne
Feb 7, 2001·Schizophrenia Bulletin·M F GreenJ Mintz
Sep 5, 2001·The American Journal of Psychiatry·D C Goff, J T Coyle
Aug 27, 2004·Schizophrenia Research·Jovier D EvansSandra Tunis
May 23, 2008·Schizophrenia Research·Matthew M KurtzJames C Seltzer
Jan 22, 2011·The Open Medicinal Chemistry Journal·Kenji Hashimoto
Nov 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepak Cyril D'SouzaJacques Schipper
Jun 1, 2012·British Journal of Pharmacology·Wojciech Danysz, Chris G Parsons
Jul 17, 2012·Neuropharmacology·Graham L CollingridgeDavid E Jane
Nov 3, 2012·British Journal of Clinical Pharmacology·Marieke Liem-MoolenaarJoop M A van Gerven
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Oct 24, 2013·Cutaneous and Ocular Toxicology·Chang-Ning LiuChris Somps
Apr 4, 2014·JAMA Psychiatry·Daniel UmbrichtLuca Santarelli
Jan 13, 2016·Drug Development and Industrial Pharmacy·Eric LyngJohn Sagartz
Mar 17, 2016·BMC Psychiatry·Yoshio HirayasuTeruhiko Higuchi
Oct 28, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Viktoria MoschettiSven Wind
Citations
Aug 24, 2018·Clinical and Translational Science·Holger RosenbrockSven Wind
Feb 10, 2020·Clinical Drug Investigation·Philip D HarveyJana Podhorna
Feb 22, 2021·The Lancet. Psychiatry·W Wolfgang FleischhackerStephane Pollentier
Dec 23, 2021·Clinical Drug Investigation·Ute BurkardTom S Chan
Oct 31, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Michael DeschSven Wind